Change of Deputy Director of the State Food and Drug Administration

01 Personnel changes of the State Food and Drug Administration

Yesterday (August 10), the official website of the Ministry of Human Resources and Social Security released the news of the appointment and removal of national staff

A person from the State Food and Drug Administration said to Cyberland that Chen Shifei retired normally, and Huang Guo was the deputy director of the State Food and Drug Administration.

According to the official website of the State Food and Drug Administration, the State Food and Drug Administration has five deputy directors, including Chen Shifei, who are responsible for different lines and have completely different background experiences.

It should be noted that, according to the official website of the State Food and Drug Administration, the newly appointed Huang Guo, in April 2017, served as the director of the information center (with a one-year trial period), and two months later, in June 2017, he served as the information center (China Foods).

There is also another deputy director of the State Food and Drug Administration, Xu Jinghe, who also has experience in the information center.

It can be seen that the information construction of the medical system is equally important

It is worth mentioning that among the five deputy directors of the State Food and Drug Administration, in addition to information professionals and supervision experts with a legal background, there is also Zhao Junning, who is mainly engaged in traditional Chinese medicine research, and will be appointed as a national drug in October 2021.

From the appointment of positions, it can be seen that the relevant departments attach great importance to traditional Chinese medicine, drug supervision, and medical informatization

Li Li, Secretary of the Party Group and Deputy Director of the State Food and Drug Administration, is also a member of the Party Group of the State Administration for Market Regulation

It can be seen from this that the pharmaceutical industry is actually under the supervision of a large national market

In terms of the main responsibilities of the State Food and Drug Administration, Cyberlane found that the State Food and Drug Administration needs to formulate relevant supervision and management policy plans and supervise the implementation of the supervision and management of drugs

Secondly, the State Food and Drug Administration is also the participating department in the revision of the National Essential Drugs List.

For enterprises, many pharmaceutical companies have started comprehensive clinical evaluation of drugs in the list of essential drugs

Sun Yuewu, a specially-appointed expert from the International Pharmaceutical Business School of China Pharmaceutical University, told Cyberland that the basic drug adjustment plan is about to be released, which means that the selection of the new version of the basic drug will officially kick off

Third, the State Food and Drug Administration organizes the monitoring, evaluation and disposal of adverse reactions of drugs and medical devices; supervises and guides the registration and production links

Fourth, in the management of licensed pharmacists, the responsibilities are also very clear
.
Licensed pharmacists have now become a necessity for pharmacies, and it is precisely because of the scarcity that the phenomenon of "certification" has been repeatedly banned; licensed pharmacists are not selling drugs, and the promotion of their status is also a point that the industry often calls for
.

03 The era of "National Unified Market" is coming

In terms of organizational framework, the State Food and Drug Administration is subordinate to the State Administration for Market Regulation
.
Judging from the current development trend of the entire market, the era of "the unified national market" is coming, and the pharmaceutical industry is no exception
.

As early as April 10 this year, the "Opinions of the Central Committee of the Communist Party of China and the State Council on Accelerating the Construction of a National Unified Market" was released
.

According to Zhang Zheng, a professor at the School of Economics of Peking University, under the "uniform big market", market services, market standards, market supervision, and consumer rights will be unified in the future
.

To promote the upgrading and iteration of the industrialization of enterprises, anti-monopoly has also become a key word
.

The "unified big market" is also reflected in the field of medicine
.

First of all, at the medical insurance level, the work of abolishing the local medical insurance supplementary catalogue has entered the final stage; secondly, in terms of centralized procurement, a unified national recruitment and procurement system has been established and gradually put into use in various places.
more transparent pricing
.
Third, online and offline, drug sales, enter the integrated supervision
.

Fourth, the pharmaceutical distribution industry may enter a critical turning point
.
For a long time, the management of pharmaceutical logistics has mainly relied on the local provincial drug regulatory authorities.
The interpretation and implementation of policies are not uniform in local supervision.
To a certain extent, various regions have formed "market segmentation" and "local protection", which hinders drug distribution enterprises from trans-regional, The merger and reorganization of cross-ownership, under the "unification of the big market", this phenomenon will change, also, may lead to the accelerated trend of retail pharmacy chain
.

Most of this is inseparable from informatization, especially in medicine.
Among the deputy directors of the State Food and Drug Administration, two have strong experience in informatization.
In the future, the degree of informatization in the pharmaceutical field will be improved and national supervision A game of chess is just around the corner
.